Ischemia-Reperfusion Injuries, Nephrology

Balmes Transplantation is an early stage pharmaceutical company with fast development timelines focused on kidney Ischemia-Reperfusion Injury (IRI), including Acute Kidney Injury (AKI) and its subsequent transition to Chronic Kidney Disease (CKD) and Kidney Transplantation (KTx).

The company was founded in 2015 in France. We are raising 5 m€ from Life Sciences-savvy investors to bring our in-vivo validated assets at the entry of Phase II clinical trials in the 24 months following the round.

We are developing drugs against kidney IRI in Cardiac Surgery-Associated-AKI and Delayed Graft Function in KTx, two conditions with high unmet medical needs for patients and payers, and no pharmacological therapeutic options.